Meeting
2020 Genitourinary Cancers Symposium
A phase II trial of regorafenib for advanced urothelial cancer (aUC) following prior chemotherapy.
Authors
Gurudatta Naik
University of Alabama at Birmingham, Birmingham, AL
Gurudatta Naik , Ulka N. Vaishampayan , Lisle Nabell , Mollie R. De Shazo , Lakshminarayanan Nandagopal , Petros Grivas , Charity Morgan , Pamela Hardwick , Guru Sonpavde
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02459119
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 498)
Abstract #
498
Poster Bd #
H21
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A prospective phase II trial of pembrolizumab plus lenvatinib in advanced adrenal cortical carcinoma after failure of platinum- and mitotane-based chemotherapy (ACCOMPLISH).
First Author: Inkeun Park
Poster
2024 ASCO Genitourinary Cancers Symposium
Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC).
First Author: Evangelia Vlachou
Poster
2023 ASCO Genitourinary Cancers Symposium
Uptake of maintenance immunotherapy and changes in upstream treatment selection in patients with advanced urothelial cancer (aUC).
First Author: Ronac Mamtani
Poster
2023 ASCO Genitourinary Cancers Symposium
Characteristics and outcomes for patients (pts) with metastatic small cell urothelial carcinoma (mSCUC).
First Author: Nathaniel R. Wilson